Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Lifecell (LIFC) -- Ignore unavailable to you. Want to Upgrade?

To: W Shakespeare who wrote (355)	5/2/1999 5:13:00 PM
From: Joe Btfsplk	Read Replies (1) \| Respond to of 395

As I understand it, the raw hide comes from tissue banks, which, by law, are non-profits. Back when sales projections were far higher, a former VP in charge of IR told me on several occasions they anticipated no difficulties in securing adequate supplies of cadaver skin for the foreseeable future. Seems it was the fall of '95 when the FDA rated Alloderm as banked human tissue, which is not subject to the same level of scrutiny as artificial products. That could change. My guess is that intense editorial commentary on the arbitrary, perhaps tyrannical nature of the FDA in years prior will tend to preclude shifts without adequate cause. As you note, sales, thus earnings estimates, have been cut dramatically from projections in the past. Based on some years of following LIFC, let me give you an unequivocal opinion on when they will turn profitable: - - - Someday, - - - - - maybe. Good luck.